The dominance of CHO cells isn't due to universal optimality but to being 'good enough' with established infrastructure. The correct approach is to identify specific molecules and manufacturing contexts where novel hosts provide a clear advantage in cost, speed, or quality that CHO cannot easily match.
While transient plant expression offers unprecedented speed for biologics production, it lacks a traditional Master Cell Bank. This introduces a unique regulatory challenge: batch-to-batch consistency is not guaranteed by a clonal cell line but depends on managing variables like plant growth and Agrobacterium infiltration efficiency.
Cell-free protein synthesis is the only platform that can site-specifically incorporate non-natural amino acids. This is a critical requirement for next-generation Antibody-Drug Conjugates (ADCs) where precise drug placement dictates efficacy. While more expensive than CHO for bulk protein, it's the only viable option for creating these advanced molecules.
The inflection point for a novel manufacturing platform's credibility isn't just an initial IND or a niche approval. It's achieving late-stage (Phase 2/3) clinical data in a major new therapeutic category, like oncology monoclonal antibodies. This signal fundamentally changes the risk calculus for both regulators and industry adopters.